MET-88
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Summary Mildronate (3-(2,2,2-trimethylhydrazine)propionate; THP; MET-88; meldonium, quaterine) is an anti-ischemic drug developed…
Aims: The aim of our investigation was to assess effectiveness of Mildronate in the treatment of aged patients with congestive…
Background: Partial fatty acid oxidation inhibitors have raised great interest since they are expected to counteract a…
MET-88, 3-(2,2,2-trimethylhydrazinium) propionate, suppresses carnitine synthesis by inhibiting (gamma-butyrobetaine hydroxylase…
Inhibition of fatty acid metabolite accumulation may be beneficial for treatment of cardiac dysfunction induced by ischemia. MET…
We previously reported that MET-88, 3-(2,2,2-trimethylhydrazinium) propionate, improved left ventricular diastolic dysfunction…
We previously reported that MET-88, 3-(2,2,2-trimethylhydrazinium) propionate, improved left ventricular diastolic dysfunction…
Abstract— We examined the effects of MET‐88 on haemodynamics and cardiac hypertrophy in rats with an aortocaval shunt (A‐V shunt…
Summary— 3‐(2,2,2‐trimethylhydrazinium) propionate (MET‐88) is an inhibitor of carnitine synthesis. This study was carried out to…